GALT Galectin Therapeutics Inc.
USHealthcareAs of 2026-07-08 16:00
Why GALT matters now
Galectin Therapeutics Inc. (GALT) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.51 with -2.17% on the session and $297.0M in market capitalization; recent performance reads 1-month +35.82% and YTD -32.09%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.0M, and EPS of $-0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.8%.
The latest indexable market news headline is "Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.00; recent insider activity includes Jamil Khurram filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.43
P/S
0.00
EV/EBITDA
-16.52
DCF Value
$-1.86
FCF Yield
-10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
21.0%
ROA
-166.6%
ROIC
-192.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.0M | $-0.08 |
| Q4 2025 | $0.00 | $-5.5M | $-0.08 |
| FY 2025 | $0.00 | $-30.8M | $-0.48 |
| Q3 2025 | $0.00 | $-8.2M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$11.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.49
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.